Clinical implications of variant allele frequencies of genes in patients with acute myeloid leukemia.
Measuring exact mutation levels alongside standard chromosome tests helps doctors more accurately predict which AML patients will benefit most from intensive versus lighter treatment.
A retrospective study of 254 AML patients shows that quantitative variant allele frequencies for 7 key mutations, integrated with cytogenetic stratification, outperform binary mutation status in risk classification, validated in an external cohort. This near-implementable refinement of ELN 2022 may guide personalized therapy intensity decisions for non-transplanted AML patients.
What the study was
- Study design
- Retrospective cohort with external validation
- Population
- AML patients, bone marrow NGS
- Sample size
- 254
- Category
- Genomics/Precision Medicine
- Maturity
- Validated
- Journal
- The Oncologist
Why it surfaced
VAF-enhanced AML risk model validated internally and externally; published in The Oncologist; directly refines ELN 2022 stratification for non-transplant patients; retrospective single-center primary cohort limits score cap.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.